IL123720A - שיטות ליצור של תת יחידות חיסוניות של פרוטאזומים שהינן מולטי-וולנטיות וקשורות באופן לא קוולנטי - Google Patents
שיטות ליצור של תת יחידות חיסוניות של פרוטאזומים שהינן מולטי-וולנטיות וקשורות באופן לא קוולנטיInfo
- Publication number
- IL123720A IL123720A IL12372096A IL12372096A IL123720A IL 123720 A IL123720 A IL 123720A IL 12372096 A IL12372096 A IL 12372096A IL 12372096 A IL12372096 A IL 12372096A IL 123720 A IL123720 A IL 123720A
- Authority
- IL
- Israel
- Prior art keywords
- proteosome
- preparation
- vaccine according
- vaccine
- determinant
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 71
- 238000004519 manufacturing process Methods 0.000 title description 17
- 229940031626 subunit vaccine Drugs 0.000 title description 3
- 229960005486 vaccine Drugs 0.000 claims abstract description 117
- 238000002360 preparation method Methods 0.000 claims abstract description 43
- 239000003599 detergent Substances 0.000 claims abstract description 36
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 238000012544 monitoring process Methods 0.000 claims abstract 5
- 230000009918 complex formation Effects 0.000 claims abstract 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims description 93
- 239000002158 endotoxin Substances 0.000 claims description 92
- 239000012466 permeate Substances 0.000 claims description 20
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical group CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 claims description 18
- 241000607768 Shigella Species 0.000 claims description 17
- 239000012510 hollow fiber Substances 0.000 claims description 16
- 239000012528 membrane Substances 0.000 claims description 16
- 239000012465 retentate Substances 0.000 claims description 15
- 239000002244 precipitate Substances 0.000 claims description 13
- 241000606999 Plesiomonas shigelloides Species 0.000 claims description 12
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 241000607760 Shigella sonnei Species 0.000 claims description 8
- 229940031348 multivalent vaccine Drugs 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 5
- 241000588653 Neisseria Species 0.000 claims description 4
- 229940115939 shigella sonnei Drugs 0.000 claims description 4
- 241000588650 Neisseria meningitidis Species 0.000 claims description 3
- 241000607000 Plesiomonas Species 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 241000588652 Neisseria gonorrhoeae Species 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims 2
- 241000607762 Shigella flexneri Species 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 abstract description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 230000000536 complexating effect Effects 0.000 description 15
- 238000000502 dialysis Methods 0.000 description 15
- 230000004044 response Effects 0.000 description 14
- 230000003053 immunization Effects 0.000 description 13
- 238000002649 immunization Methods 0.000 description 13
- 208000004429 Bacillary Dysentery Diseases 0.000 description 11
- 206010040550 Shigella infections Diseases 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 201000005113 shigellosis Diseases 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- 101710116435 Outer membrane protein Proteins 0.000 description 8
- 241000147000 Shigella flexneri 2a Species 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 7
- 230000005875 antibody response Effects 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 231100000518 lethal Toxicity 0.000 description 7
- 230000001665 lethal effect Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000013341 scale-up Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 206010035664 Pneumonia Diseases 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000002485 urinary effect Effects 0.000 description 5
- 108010028921 Lipopeptides Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 238000011012 sanitization Methods 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241001212279 Neisseriales Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000635 electron micrograph Methods 0.000 description 3
- 150000002270 gangliosides Chemical class 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 230000002516 postimmunization Effects 0.000 description 3
- 230000003134 recirculating effect Effects 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- -1 GD3 ganglioside Chemical class 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000002011 intestinal secretion Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 241000902235 Oides Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000607766 Shigella boydii Species 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000776 antibody secreting cell Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000008949 local secretion Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000011232 storage material Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940031572 toxoid vaccine Drugs 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/008—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US385995P | 1995-09-18 | 1995-09-18 | |
| PCT/US1996/015002 WO1997010844A1 (en) | 1995-09-18 | 1996-09-18 | Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL123720A0 IL123720A0 (en) | 1998-10-30 |
| IL123720A true IL123720A (he) | 2002-02-10 |
Family
ID=21707938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12372096A IL123720A (he) | 1995-09-18 | 1996-09-18 | שיטות ליצור של תת יחידות חיסוניות של פרוטאזומים שהינן מולטי-וולנטיות וקשורות באופן לא קוולנטי |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6476201B1 (he) |
| EP (1) | EP0854729B2 (he) |
| JP (2) | JP4033489B2 (he) |
| KR (1) | KR19990045763A (he) |
| CN (1) | CN1211192A (he) |
| AT (1) | ATE261313T1 (he) |
| BR (1) | BR9610484A (he) |
| CA (1) | CA2232410C (he) |
| CZ (1) | CZ298460B6 (he) |
| DE (1) | DE69631835T3 (he) |
| DK (1) | DK0854729T3 (he) |
| EA (1) | EA199800208A1 (he) |
| ES (1) | ES2217325T5 (he) |
| HU (1) | HUP9901577A3 (he) |
| IL (1) | IL123720A (he) |
| MX (1) | MX9802128A (he) |
| NO (1) | NO320074B1 (he) |
| PL (1) | PL325604A1 (he) |
| PT (1) | PT854729E (he) |
| WO (1) | WO1997010844A1 (he) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5961970A (en) * | 1993-10-29 | 1999-10-05 | Pharmos Corporation | Submicron emulsions as vaccine adjuvants |
| WO1999061053A1 (en) * | 1998-05-29 | 1999-12-02 | Chiron Corporation | Combination meningitidis b/c vaccines |
| WO2000066741A2 (en) | 1999-04-30 | 2000-11-09 | Chiron S.P.A. | Conserved neisserial antigens |
| NZ515935A (en) | 1999-05-19 | 2004-01-30 | Chiron S | Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis |
| EP1721618A3 (en) * | 2000-02-15 | 2007-01-10 | ID Biomedical Corporation of Quebec | Proteosome influenza vaccine composition |
| CA2400468C (en) | 2000-02-15 | 2012-12-18 | Intellivax International Inc. | Proteosome influenza vaccine |
| NZ521531A (en) | 2000-02-28 | 2005-12-23 | Chiron S | Heterologous expression of neisserial proteins |
| US7524509B2 (en) | 2001-03-09 | 2009-04-28 | Id Biomedical Corporation Of Quebec | Proteosome-liposaccharide vaccine adjuvant |
| US20060057160A1 (en) * | 2002-08-02 | 2006-03-16 | Ralph Biemans | Vaccine composition |
| HUE031886T2 (en) | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
| US7255867B2 (en) * | 2002-11-15 | 2007-08-14 | Id Biomedical Corporation Of Quebec | Vaccine |
| GB0316560D0 (en) * | 2003-07-15 | 2003-08-20 | Chiron Srl | Vesicle filtration |
| US7368537B2 (en) * | 2003-07-15 | 2008-05-06 | Id Biomedical Corporation Of Quebec | Subunit vaccine against respiratory syncytial virus infection |
| US20050152919A1 (en) * | 2003-09-15 | 2005-07-14 | Id Biomedical Corporation Of Quebec | Measles subunit vaccine |
| WO2005042017A1 (en) | 2003-10-22 | 2005-05-12 | Id Biomedical Corporation Of Quebec | Compositions and methods for activating innate and allergic immunity |
| CN101039691B (zh) | 2004-06-25 | 2013-07-31 | 魁北克益得生物医学公司 | 用于治疗神经疾病的组合物和方法 |
| EP1778283A2 (en) * | 2004-06-30 | 2007-05-02 | ID Biomedical Corporation of Quebec | Vaccine compositions for treating coronavirus infection |
| US7552948B2 (en) | 2006-03-29 | 2009-06-30 | Tokai Rubber Industries, Ltd. | Quick connector |
| CN110064053A (zh) * | 2006-08-07 | 2019-07-30 | 哈佛大学校长及研究员协会 | 蛋白质基质疫苗及这种疫苗的制备和给药方法 |
| BRPI0715396B8 (pt) * | 2006-08-07 | 2021-05-25 | Harvard College | método de produção de uma composição para vacina |
| EP2069054A1 (en) * | 2006-08-30 | 2009-06-17 | GE Healthcare Bio-Sciences Corp. | System and method for characterizing membranes and membrane filtration devices |
| UA99659C2 (uk) * | 2008-05-30 | 2012-09-10 | Дзе Ю.Ес.Ей., Ес Репрезентед Бай Дзе Секретарі Оф Дзе Армі, Он Бехаф Оф Уолтер Рід Армі | Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування |
| CN102686238A (zh) * | 2009-09-09 | 2012-09-19 | 马特里瓦克斯研究和开发公司 | 具有改善的免疫原性的蛋白质基质疫苗 |
| AU2015321698B2 (en) * | 2014-09-24 | 2018-06-28 | The United States Of America As Represented By The Secretary Of The Navy | Combined enterotoxigenic Escherichia coli and Campylobacter jejuni recombinant construct |
| CA3208643A1 (en) | 2021-01-18 | 2022-07-21 | Conserv Bioscience Limited | Coronavirus immunogenic compositions, methods and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4707543A (en) * | 1985-09-17 | 1987-11-17 | The United States Of America As Represented By The Secretary Of The Army | Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines |
| RU1522494C (ru) * | 1987-06-16 | 1994-11-15 | Научно-производственное объединение "Иммунопрепарат" | Способ получения инактивированной вакцины гриппа |
| RU2023448C1 (ru) * | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
| US5145702A (en) * | 1988-09-19 | 1992-09-08 | Opta Food Ingredients, Inc. | Hydrophobic protein microparticles and preparation thereof |
| EP0449958B9 (en) * | 1988-12-19 | 2003-05-28 | American Cyanamid Company | Meningococcal class 1 outer-membrane protein vaccine |
| US5102989A (en) * | 1991-03-15 | 1992-04-07 | Merck & Co., Inc. | Method of stabilizing recombinant hepatitis B virus surface proteins from recombinant host cells |
| CA2139517A1 (en) * | 1992-07-20 | 1994-02-03 | Paul M. Keller | Immunological conjugates of ompc and hiv-specific selected principal neutralization epitopes |
| US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| WO1995011700A1 (en) * | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| CA2400468C (en) * | 2000-02-15 | 2012-12-18 | Intellivax International Inc. | Proteosome influenza vaccine |
-
1996
- 1996-09-18 CN CN96197616A patent/CN1211192A/zh active Pending
- 1996-09-18 KR KR1019980702007A patent/KR19990045763A/ko not_active Withdrawn
- 1996-09-18 PL PL96325604A patent/PL325604A1/xx unknown
- 1996-09-18 US US09/043,529 patent/US6476201B1/en not_active Expired - Lifetime
- 1996-09-18 EP EP96932269A patent/EP0854729B2/en not_active Expired - Lifetime
- 1996-09-18 PT PT96932269T patent/PT854729E/pt unknown
- 1996-09-18 JP JP51287597A patent/JP4033489B2/ja not_active Expired - Lifetime
- 1996-09-18 ES ES96932269T patent/ES2217325T5/es not_active Expired - Lifetime
- 1996-09-18 DE DE69631835T patent/DE69631835T3/de not_active Expired - Lifetime
- 1996-09-18 EA EA199800208A patent/EA199800208A1/ru unknown
- 1996-09-18 CZ CZ0081998A patent/CZ298460B6/cs not_active IP Right Cessation
- 1996-09-18 AT AT96932269T patent/ATE261313T1/de not_active IP Right Cessation
- 1996-09-18 BR BR9610484-8A patent/BR9610484A/pt not_active Application Discontinuation
- 1996-09-18 IL IL12372096A patent/IL123720A/he not_active IP Right Cessation
- 1996-09-18 DK DK96932269T patent/DK0854729T3/da active
- 1996-09-18 HU HU9901577A patent/HUP9901577A3/hu unknown
- 1996-09-18 WO PCT/US1996/015002 patent/WO1997010844A1/en not_active Ceased
- 1996-09-18 CA CA002232410A patent/CA2232410C/en not_active Expired - Lifetime
-
1998
- 1998-03-17 NO NO19981189A patent/NO320074B1/no not_active IP Right Cessation
- 1998-03-18 MX MX9802128A patent/MX9802128A/es unknown
-
2003
- 2003-10-24 JP JP2003365270A patent/JP2004099619A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NO981189L (no) | 1998-05-14 |
| WO1997010844A1 (en) | 1997-03-27 |
| DE69631835T2 (de) | 2005-02-10 |
| BR9610484A (pt) | 2001-09-11 |
| HUP9901577A3 (en) | 2000-03-28 |
| ES2217325T5 (es) | 2009-04-01 |
| DE69631835T3 (de) | 2009-03-05 |
| CN1211192A (zh) | 1999-03-17 |
| MX9802128A (es) | 1998-11-29 |
| JP2000507913A (ja) | 2000-06-27 |
| US6476201B1 (en) | 2002-11-05 |
| CA2232410C (en) | 2003-06-17 |
| CZ298460B6 (cs) | 2007-10-10 |
| EP0854729A1 (en) | 1998-07-29 |
| ES2217325T3 (es) | 2004-11-01 |
| US20020164357A1 (en) | 2002-11-07 |
| EP0854729B2 (en) | 2008-10-22 |
| EP0854729A4 (en) | 2000-02-02 |
| DE69631835D1 (de) | 2004-04-15 |
| PT854729E (pt) | 2004-08-31 |
| KR19990045763A (ko) | 1999-06-25 |
| EP0854729B1 (en) | 2004-03-10 |
| DK0854729T3 (da) | 2004-07-12 |
| NO320074B1 (no) | 2005-10-17 |
| JP4033489B2 (ja) | 2008-01-16 |
| NO981189D0 (no) | 1998-03-17 |
| JP2004099619A (ja) | 2004-04-02 |
| CA2232410A1 (en) | 1997-03-27 |
| IL123720A0 (en) | 1998-10-30 |
| ATE261313T1 (de) | 2004-03-15 |
| PL325604A1 (en) | 1998-08-03 |
| EA199800208A1 (ru) | 1998-10-29 |
| CZ81998A3 (cs) | 1998-10-14 |
| HUP9901577A2 (hu) | 1999-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0854729B1 (en) | Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines | |
| EP1286696B1 (en) | Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup a and process for the production thereof | |
| CA2123355C (en) | Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci | |
| US6558677B2 (en) | Vaccine against gram negative bacteria | |
| Frasch et al. | Outer membrane protein vesicle vaccines for meningococcal disease | |
| EP2482847B2 (en) | Purification of bacterial vesicles | |
| EP0688206B1 (en) | Vaccine delivery system and shelf-stable precursor solution for remote encapsulation of active ingredients | |
| BE1022875B1 (fr) | Compositions pour une immunisation contre staphylococcus aureus | |
| JP2012521404A (ja) | 肺炎球菌血清型１４の糖を含む組み合わせ | |
| Muttilainen et al. | TheNeisseria meningitidisouter membrane protein P1 produced inBacillus subtilisand reconstituted into phospholipid vesicles elicits antibodies to native P1 epitopes | |
| Gotschlich | Meningococcal meningitis | |
| AU751063B2 (en) | Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines | |
| Jiskoot et al. | Immunogenic activity of gonococcal protein I in mice with three different lipoidal adjuvants delivered in liposomes and in complexes | |
| Andersen et al. | Outer membrane vesicle vaccines made from short-chain lipopolysaccharide mutants of serogroup B Neisseria meningitidis: effect of the carbohydrate chain length on the immune response | |
| HK1012991B (en) | Vaccine delivery system and shelf-stable precursor solution for remote encapsulation of active ingredients | |
| Lipld | Rough LPs. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |